𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols

✍ Scribed by Mandelli, F; Latagliata, R; Avvisati, G; Fazi, P; Rodeghiero, F; Leoni, F; Gobbi, M; Nobile, F; Gallo, E; Fanin, R

Book ID
110055475
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
125 KB
Volume
17
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adding arabinosylcytosine to idarubicin
Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia: Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study. LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141–6.
✍ Elihu Estey; Miguel A. Sanz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 77 KB